We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genincode Plc | LSE:GENI | London | Ordinary Share | GB00BL97B504 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.80 | 3.60 | 4.00 | 3.80 | 3.80 | 3.80 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 2.16M | -7.02M | -0.0396 | -0.96 | 6.72M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/7/2022 19:45 | In which case the business is in for next to nothing (They said they were holding off on spending)....time to top up | barbello | |
26/7/2022 17:50 | Yes it can Nice volume today not sure where the stock came from - but the price hasn't dropped. | toffeeman | |
26/7/2022 16:26 | Cash as at 31 Dec was 14.6mMarket Cap about 16mCan that be right? | barbello | |
26/7/2022 12:34 | yes share price is too low. That's worth x 2 at least. Hope the FDA submission comes in next 30 days so clock is ticking for December close. | madmonkflin | |
26/7/2022 06:22 | This (paid for) trial will determine the future for the company - no reason to think it won't be positive but market not impressed! | toffeeman | |
31/5/2022 07:36 | https://www.investor | barbello | |
16/5/2022 14:36 | 06/04/2022 07:01 UK Regulatory (RNS & others) GENinCode PLC Director Appointment LSE:GENI Genincode Plc " ... Matthew Walls, CEO of GENinCode Plc commented : " We are delighted that Felix is joining as a Non-Executive Director. Felix can offer us invaluable insights into the FDA as we start to look towards commericalisation in the US later this year, and his many years of experience in key roles in the industry will be a huge benefit to us. His depth of knowledge in precision medicine and regulatory affairs is second-to-none and we are looking forward to capitalising on his expertise." ..." Early last month, GENI was expressing confidence about commercialisation in the US later this year. Have GENI received the FDA response to pre-submission (filed on 10th. January) yet? And what's happening with FDA Breakthrough Device Designation? I look forward to GENI updating us on these matters tomorrow morning. | hedgehog 100 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions